Citations

Clear

1792 citation(s) found for "Stephanie".

Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children’s Oncology Group Phase I Consortium Trial
Green, Adam L. , Minard, Charles G. , Liu, Xiaowei , Pinkney, Kerice , Harris, Lauren S., Link, Gabrielle, DeSisto, John , Voss, Stephan D. , Nelson, Marvin D. , Fox, Elizabeth , Weigel, Brenda J. , Bender, Julia Glade , Safgren, Stephanie L , Pinkney, Kerice , Harris, Lauren , Link, Gabrielle , DeSisto, John , Voss, Stephan D , Nelson, Marvin D , Reid, Joel M , Fox, Elizabeth , Weigel, Brenda J , Glade-Bender, Julia , Safgren, Stephanie L. , Reid, Joel M.

Mayo Clinic

Clinical Cancer Research | February 25, 2025 | Volume: 31 | Issue: 9 | Pages: 1587-1595

10.1158/1078-0432.ccr-24-2754 | PMID 39998852 Get It

Abstract Purpose: Selinexor is a first-in-class, central nervous system (CNS)–penetrant, oral inhibitor of exportin 1 (XPO1), the main nuclear exporter of many key tumor suppressors. We report a phase I trial of selinexor in children and adolescents with recurrent CNS and solid tumors (NCT02323880). Patients and Methods: A rolling six design was used to evaluate the maximum tolerated dose (MTD) and first dose pharmacokinetics of selinexor administered once (35–45 mg/m2) or twice (20–35 mg/m2) weekly during a 28-day cycle (part A). Ten additional patients with high-grade glioma (HGG) were treated at the MTD administered once weekly (part B). Results: In part A, 49 patients were enrolled. Continuous twice weekly dosing was limited by extended hematologic toxicity. The MTD on a twice weekly schedule for 3 weeks on/1 week off (twice weekly 3/1) was 20 mg/m2/dose. Dose-limiting toxicities (DLTs) on this schedule included fatigue, acute reversible neurologic changes, neutropenia, thrombocytopenia, and aspartate aminotransferase/alanine aminotransferase increase. On a continuous once weekly schedule, the MTD was 35 mg/m2/dose; DLTs included seizure and thrombocytopenia. In part B (HGG expansion), there were no additional DLTs observed. Non-DLTs included lymphopenia, leukopenia, neutropenia, thrombocytopenia, anorexia, fatigue, hypophosphatemia, nausea, and vomiting. There were no objective responses. The median number of cycles received was 1 (range, 1–9); eight of 59 patients (13.5%) received 5 to 9 cycles, five of whom had HGG. Conclusions: Selinexor-related toxicities were primarily hematologic and neurologic, requiring dose or dose-frequency reduction. The MTD and recommended initial phase II dose of selinexor in children and adolescents with recurrent solid and CNS tumors is 35 mg/m2/dose once weekly.
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status
Lambertini, Matteo , Blondeaux, Eva , Tomasello, Loredana Maria, Agostinetto, Elisa , Hamy, Anne‐Sophie , Kim, Hee Jeong , Franzoi, Maria Alice , Bernstein‐Molho, Rinat , Hilbers, Florentine , Pogoda, Katarzyna , Bajpai, Jyoti , Phillips, Kelly‐Anne , Rousset‐Jablonski, Christine , Renaud, Tiphaine , Cui, Wanyuan , Wong, Stephanie M. , Ruddy, Kathryn J. , Marchis, Laura De , Wildiers, Hans , Bajpai, Jyoti , Ignatiadis, Michail , Moore, Halle C F , Partridge, Ann H , Phillips, Kelly-Anne , Toss, Angela , Rousset-Jablonski, Christine , Criscitiello, Carmen , Ferrari, Alberta , Fruscio, Robert , Cui, Wanda , Wong, Stephanie M , Vernieri, Claudio , Ruddy, Kathryn J , Dieci, Maria Vittoria , Matikas, Alexios , Rozenblit, Mariya , Villarreal-Garza, Cynthia , De Marchis, Laura , Puglisi, Fabio , Rodriguez-Wallberg, Kenny A , Livraghi, Luca , Bruzzone, Marco , Boni, Luca , Balmaña, Judith , Lambertini, Matteo , Hamy, Anne-Sophie , Pogoda, K. , Wildiers, Hans , Ignatiadis, Michail , Moore, Halle C. F. , Partridge, Ann H. , Paluch–Shimon, Shani , Fruscio, Robert , Dieci, Maria Vittoria , Villarreal‐Garza, Cynthia , Duhoux, François P. , Livraghi, Luca , Bruzzone, Marco , Balmañà, Judith

Mayo Clinic

Journal of Clinical Oncology | February 24, 2025 | Volume: 43 | Issue: 14 | Pages: 1706-1719

10.1200/jco-24-01334 | PMID 39993249 Get It

PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene ( BRCA1 v BRCA2 ) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. METHODS This was an international, multicenter, hospital-based, retrospective cohort study that included 4,752 patients harboring germline pathogenic/likely pathogenic variants (PVs) in BRCA1 or BRCA2 , who were diagnosed with stage I-III invasive breast cancer at 40 years or younger between January 2000 and December 2020 in 78 centers worldwide (ClinicalTrials.gov identifier: NCT03673306 ). RESULTS Compared with BRCA2 carriers (n = 1,683), BRCA1 carriers (n = 3,069) had more frequently hormone receptor–negative (74.4% v 15.5%) and high-grade (77.5% v 49.1%) tumors. Similar outcomes were observed in BRCA1 and BRCA2 carriers but with a different pattern and risk of disease-free survival events over time. Compared with patients tested for BRCA at diagnosis (ie, between 2 months before and up to 6 months after diagnosis; n = 1,671), those tested before diagnosis (ie, any time up to 2 months before diagnosis; n = 411) had smaller tumors (T1: 61.3% v 32.4%), less nodal involvement (N0: 65.9% v 50.8%), less frequently received chemotherapy (84.4% v 92.9%), and axillary dissection (37.5% v 47.4%). Patients tested before diagnosis had better overall survival (OS; unadjusted hazard ratio [HR], 0.61 [95% CI, 0.40 to 0.92]); however, this result lost statistical significance after adjustment for potential confounders including tumor stage (adjusted HR, 0.74 [95% CI, 0.47 to 1.15]). CONCLUSION This global study provides evidence on the different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers. Identifying a BRCA PV in healthy individuals was associated with earlier-stage breast cancer diagnosis and lower treatment burden, as well as better unadjusted OS.
Challenges to and considerations of designing cancer prevention trials
Enserro, Danielle , Duan, Fenghai , Pugh, Stephanie L. , Enserro, Danielle M , Gunn, Heather J., Gunn, Heather , Elsaid, Mohamed I

Mayo Clinic

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 49-55

10.1093/jncimonographs/lgae044 | PMID 39989045 Get It

Abstract Prevention trials in oncology are some of the most important cancer clinical trials that can be designed, implemented, analyzed, and interpreted. They are pivotal in the goal of stopping the development of cancer before it starts. Prevention trials are unique in that they not only have some of the same requirements and challenges as treatment trials but also have challenges that may make their design more complex. This paper aims to discuss some types of prevention trials and highlight their most common design challenges, including large sample size requirements, slow accrual rates with long accrual duration, extended follow-up periods with trial adherence issues and missing data, endpoints that require extended follow-up or have a high level of confounding, and problems with optimizing study design. This article provides real study examples and suggestions for designing prevention clinical trials while mitigating the known issues they face.
When to adjust for multiplicity in cancer clinical trials
Unger, Joseph M. , Duan, Fenghai , Dressler, Emily V. , Enserro, Danielle , Pugh, Stephanie L. , Dressler, Emily V , Unger, Joseph M , Mazza, Gina L , Elsaid, Mohamed I , Snavely, Anna C.

Mayo Clinic

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 3-9

10.1093/jncimonographs/lgae051 | PMID 39989044 Get It

Abstract Interpreting cancer clinical trial results often depends on addressing issues of multiplicity. When testing multiple hypotheses, unreliable findings can occur by chance due to the inflation of the type I error rate, the probability of mistakenly rejecting the null hypothesis when the null hypothesis is true. In this setting, researchers may often set the type I error rate (or the alpha level) low to limit false positive findings and the interpretation of a causal relationship where none exists. Conversely, overly conservative type I error control may result in declaring findings, that do not meet multiplicity-adjusted alpha levels, as false when they are actually true, reducing opportunities for new discovery. This presentation focuses on multiplicity adjustment in the context of clinical trials conducted within the NCI’s Community Oncology Research Program (NCORP). Because federally sponsored trials often require long-term participation from patients and represent a substantial investment by taxpayers, striking the right balance between optimizing what is learned from these trials, while avoiding false positive results, should be a priority.
Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP)
Snavely, Anna C. , Lee, Ju-Whei, Pugh, Stephanie L. , Arnold, Kathryn B. , Smith, Sydney A. , Tan, Angelina D, Dockter, Travis , Zahrieh, David M. , Gunn, Heather J., Gunn, Heather , Barlow, William E. , Culakova, Eva , Kittel, Carol , Hanlon, Bret M. , Tan, Angelina D, Dressler, Emily V.

Mayo Clinic

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 65-72

10.1093/jncimonographs/lgae048 | PMID 39989039 Get It

Abstract The intracluster correlation coefficient (ICC) measures the correlation of observations within clusters and is a key parameter for power and sample size calculations for cluster randomized trials (CRTs). To facilitate the design of future CRTs within the National Cancer Institute Community Oncology Research Program (NCORP), all studies from the NCORP website were reviewed to identify completed CRTs. ICCs for primary and secondary outcomes (when available) were ascertained from these trials and summarized in this article as a resource for future trial development. Although ICCs are relatively small for many outcome cluster combinations, that is not always the case, so consideration should always be given to the specific outcome of interest, trial design, and type of cluster when estimating an ICC to facilitate trial development.
Practical design considerations for cluster randomized controlled trials: lessons learned in community oncology research
Dressler, Emily V. , Pugh, Stephanie L. , Zahrieh, David M. , Gunn, Heather J., Dressler, Emily V , Gunn, Heather , Unger, Joseph M. , Snavely, Anna C.

Mayo Clinic

JNCI Monographs | February 24, 2025 | Volume: 2025 | Issue: 68 | Pages: 56-64

10.1093/jncimonographs/lgae053 | PMID 39989035 Get It

Abstract Cancer care delivery research trials conducted within the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) routinely implement interventions at the practice or provider level, necessitating the use of cluster randomized controlled trials (cRCTs). The intervention delivery requires cluster-level randomization instead of participant-level, affecting sample size calculation and statistical analyses to incorporate correlation between participants within a practice. Practical challenges exist in the conduct of these cRCTs due to unique trial network infrastructures, including the possibility of unequal participant accrual totals and rates and staggered study initiation by clusters, potentially with differences between randomized arms. Execution of cRCT designs can be complex, ie, if some clusters do not accrue participants, unintended cluster-level crossover occurs, how best to identify appropriate cluster-level stratification, timing of randomization, and multilevel eligibility criteria considerations. This article shares lessons learned with potential mitigation strategies from 3 NCORP cRCTs.
Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy
Schwarting, Stéphanie Kristina , Bieber, Thomas , Siepen, Fabian aus dem , Schwarting, Julian , Grabmaier, Ulrich , Maßberg, Steffen , Maurer, Mathew S. , Kääb, Stefan , Davies, Daniel R. , Aus dem Siepen, Fabian , Schwarting, Julian , Grabmaier, Ulrich , Massberg, Steffen , Maurer, Mathew S , Kääb, Stefan

Mayo Clinic

Circulation: Heart Failure | February 18, 2025 | Volume: 18 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.124.011796 | PMID 39963776 Get It

Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims to explore the use of these medications in ATTR-CM, considering the disease’s stage and patient-specific issues, such as fluid homeostasis, autonomic dysfunction, conduction disorders, low and fixed stroke volumes, and decreased functional capacity. As our understanding of this condition deepens, it is important to reassess the impact of contemporary heart failure medication in ATTR-CM. Finally, the relevance of guideline recommendations for heart failure drugs based on left ventricular ejection fraction should be reconsidered in the context of ATTR-CM.
Artificial Intelligence–Based Classification of Renal Oncocytic Neoplasms: Advancing From a 2-Class Model of Renal Oncocytoma and Low-Grade Oncocytic Tumor to a 3-Class Model Including Chromophobe Renal Cell Carcinoma
Innani, Shubham , Ebare, Kingsley, Sangoi, Ankur R. , Hirsch, Michelle S. , Baheti, Bhakti , Idrees, Muhammad T. , Sangoi, Ankur R , Collins, Katrina , Saad, Mohammed, Siegmund, Stephanie , Williamson, Sean R. , Maclean, Fiona M. , Matoso, Andres , Gondim, Dibson , Acosta, Andrés , Bakas, Spyridon

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 17, 2025 | Volume: 149 | Issue: 10 | Pages: 922-929

10.5858/arpa.2024-0374-oa | PMID 39957180 Get It

Context.— Distinguishing between renal oncocytic tumors, such as renal oncocytoma (RO), and a subset of tumors with overlapping characteristics, including the recently identified low-grade oncocytic tumor (LOT), can present a diagnostic challenge for pathologists owing to shared histopathologic features. Objective.— To develop an automatic computational classifier for stratifying whole slide images of biopsy and resection specimens into 2 distinct groups: RO and LOT. Design.— A total of 269 whole slide images from 125 cases across 6 institutions were collected. A weakly supervised attention-based multiple-instance–learning deep learning (DL) model was trained and initially evaluated through 5-fold cross validation with case-level stratification, followed by validation using an independent holdout data set. Quantitative performance evaluation was based on accuracy and the area under the receiver operating characteristic curve (AUC). Results.— The developed model data set yielded generalizable performance, with a 5-fold average testing accuracy of 84% (AUC = 0.78), and a closely aligning accuracy of 83% (AUC = 0.92) on the independent holdout data set. Conclusions.— The proposed artificial intelligence approach contributes toward a comprehensive solution for addressing commonly encountered renal oncocytic neoplasms, encompassing well-established entities like RO along with the challenging “gray zone” LOT, thereby proving applicable in clinical practice.
Incisional Hernia Risk Reduction for Living Kidney Donors: Kidney Extraction Site Matters
Punukollu, Rachana , Ohara, Stephanie , Alexandru, Nica, Cosentino, Christopher P., Frasco, Peter E. , Andrews, Paul E. , Nica, Alexandru , Briggs, Logan G , Cosentino, Christopher, Frasco, Peter, Andrews, Paul , Mao, Shennen, Punukollu, Rachana , Arias, Sandra, Briggs, Logan , Nguyen, Michelle , Mao, Shennen A. , Heimbach, Julie K. , Jadlowiec, Caroline C.

Mayo Clinic

Journal of the American College of Surgeons | February 13, 2025 | Volume: 241 | Issue: 2 | Pages: 195-202

10.1097/xcs.0000000000001356 | PMID 39945456 Get It

BACKGROUND: Although most transplant centers preferentially offer minimally invasive approaches to donor nephrectomies, there remains less standardization specific to the kidney extraction site. This study aimed to evaluate incisional hernia occurrence in living kidney donors based on kidney extraction site location. STUDY DESIGN: This was a retrospective study of all donors who underwent minimally invasive living donor nephrectomies at the Mayo Clinic Arizona between 2011 and 2023 with a 2-year external validation cohort from Mayo Clinic Florida and Mayo Clinic Minnesota. The cohort was divided into 2 groups based on the kidney extraction site type: midline infraumbilical and Pfannenstiel. RESULTS: In the primary cohort, incisional hernia occurrence was observed in 1.2% of donors with an infraumbilical midline kidney extraction site compared with 0.1% with a Pfannenstiel extraction site (p = 0.04). Donors with an infraumbilical midline kidney extraction site were more likely to be men (50.8% vs 23.3%, p < 0.0001), have a higher BMI (mean 27.2 vs 26 kg/m2, p < 0.0001), and have current or former tobacco use (p = 0.002). There were no differences in incisional hernia occurrence when comparing minimally invasive surgical techniques (p = 0.52). In the external validation cohort, hernia occurrence was observed in 4.5% of donors with a midline incision compared with 0.0% with a Pfannenstiel incision (p = 0.09). Using combined data from the 3 sites, the use of a Pfannenstiel incision as the extraction site was associated with significantly lower odds of developing a hernia compared with the infraumbilical midline incision (odds ratio 0.06, 95% CI 0.008 to 0.456). CONCLUSIONS: Although the risk of hernia in living kidney donors is generally low, the use of a Pfannenstiel incision for kidney extraction appears to offer an additional incremental reduction in risk.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Inaba, Hiroto , Teachey, David T. , Annesley, Colleen , Batra, Sandeep , Beck, Jill C., Cooper, Stacy , Dallas, Mari , Oliveira, Satiro De , Kelly, Kara M. , Kohorst, Mira A. , Kutny, Matthew A. , Lee‐Miller, Cathy , Ludwig, Kathleen , Madden, Lisa, Maloney, Kelly W. , Massaro, Stephanie, Morocco, Perry , Muller, Brad, Murphy, Lindsey , Nardi, Valentina , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Wong, Victor , Yanik, Gregory A. , Stehman, Katie, Inaba, Hiroto , Colace, Susan I. , Kitko, Carrie L. , Lacayo, Norman James , Mangum, David Spencer , McCall, David C. , Shah, Bijal , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 41-62

10.6004/jnccn.2025.0006 | PMID 39938467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.